Transforming Growth Factor-??1 Plasma Levels in Stable Renal Allograft Recipients Under Different Immunosuppression

Gr, Hetzel; Plum, J; Özcan, Filiz; Heering, P.; Grabensee, B

doi:10.1097/00007890-200102270-00022

Cited by 4 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous data (Radwan‐Oczko et al 2006) showed an insignificantly higher TGF‐ β 1 plasma level in patients treated with cyclosporine compared with healthy controls and tacrolimus‐treated patients. These findings were not confirmed in other investigations (Hughes et al 1999, Hetzel et al 2001).…”

Section: Discussioncontrasting

confidence: 88%

Transforming growth factor‐β1 gene expression and cyclosporine A‐induced gingival overgrowth: a pilot study

Radwan-Oczko¹,

Boratyńska

Ziętek³

et al. 2008

J Clinic Periodontology

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 88%

Transforming growth factor‐β1 gene expression and cyclosporine A‐induced gingival overgrowth: a pilot study

Radwan-Oczko¹,

Boratyńska

Ziętek³

et al. 2008

J Clinic Periodontology

View full text Add to dashboard Cite

show abstract

“…However, a disadvantage of these studies may be that differences in the extent of morphologic damage between groups, rather than differences in the effects of the various types of medication themselves, account for any change in the level of expression of TGF-␤ and ECM-related components (20). Studies in protocol renal biopsies that have compared the effects of CsA and tacrolimus on intragraft TGF-␤ expression have shown discordant results (21)(22)(23)(24).…”

mentioning

confidence: 99%

Molecular Comparison of Calcineurin Inhibitor–Induced Fibrogenic Responses in Protocol Renal Transplant Biopsies

Groningen

Scholten²,

Lelieveld³

et al. 2006

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

The calcineurin inhibitor cyclosporine (CsA) induces a fibrogenic response that may lead to scarring of the renal allograft. This study investigated whether tacrolimus, a novel calcineurin inhibitor, exerts fibrogenic effects to a similar extent. Sixty patients were enrolled in a randomized study: 29 received CsA, and 31 received tacrolimus. Patients were subjected to tailored exposure-controlled calcineurin inhibitor regimens. Protocol biopsies were obtained at the time of transplantation and 6 and 12 mo after transplantation. Cortical TGF-␤ and collagens ␣1(I) and ␣1(III) mRNA steady-state levels were determined with real-time PCR. The extent of protein deposition of TGF-␤, ␣-smooth muscle actin, and interstitial collagens in the renal cortex was quantified with computer-assisted image analysis. The extent of interstitial collagen deposition measured with Sirius red and the accumulation of ␣-smooth muscle actin and TGF-␤ protein after 6 and 12 mo were similar for both immunosuppressive regimens. mRNA levels of TGF-␤ and collagens ␣1(I) and ␣1(III) were not significantly different in the treatment groups either. It is concluded that the fibrogenic response in renal allografts is similar in patients who receive CsA-based regimens and patients who receive tacrolimus-based regimens.

show abstract

Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A

Waiser

Schneider

Eljazyfer

et al. 2006

Clinical Immunology

View full text Add to dashboard Cite

Transforming Growth Factor-??1 Plasma Levels in Stable Renal Allograft Recipients Under Different Immunosuppression

Cited by 4 publications

References 3 publications

Transforming growth factor‐β1 gene expression and cyclosporine A‐induced gingival overgrowth: a pilot study

Transforming growth factor‐β1 gene expression and cyclosporine A‐induced gingival overgrowth: a pilot study

Molecular Comparison of Calcineurin Inhibitor–Induced Fibrogenic Responses in Protocol Renal Transplant Biopsies

Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A

Contact Info

Product

Resources

About